Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Exelixis gets additional funding for GSK deal

Executive Summary

Exercising the option under a 2005 amendment to its 2002 deal with GSK, Exelixis has chosen to develop XL784, XL647, and XL999 via a third-party arrangement called Symphony Evolution, a financing and clinical development vehicle, formed by Symphony Capital and other investors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register